# Johnson & Johnson (JNJ)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/JNJ/primer

## Business Model

---
ticker: JNJ
step: 01
generated: 2026-05-11
source: quick-research
---

### Johnson & Johnson (JNJ) — Business Overview

#### Business Description
Johnson & Johnson is a fully consolidated pharmaceutical + medical-technology company following the May 2023 separation of its consumer health division (Kenvue, since acquired by Kimberly-Clark for $48.7B announced November 2025). Today's "New J&J" operates two segments: **Innovative Medicine** (pharmaceuticals, ~64% of revenue) and **MedTech** (medical devices, ~36%). The company sells globally, with growth led by oncology (Darzalex, Carvykti), immunology (Tremfya replacing Stelara), and cardiovascular medtech (Abiomed, Shockwave). 2026 represents an inflection point as Stelara biosimilar erosion is largely "in the rearview" and the company targets ~$100.5B in 2026 revenue.

#### Revenue Model
Two segments:
- **Innovative Medicine** ($60.4B FY25, +6% YoY) — patent-protected branded pharmaceuticals across six therapeutic areas:
  - **Oncology** (~$25B+) — Darzalex (myeloma), Carvykti (CAR-T cell therapy), Erleada (prostate), Rybrevant/Lazcluze (NSCLC), Imbruvica
  - **Immunology** — Tremfya, Stelara (off-patent / biosimilarized), Simponi/Simponi Aria, Remicade
  - **Neuroscience** — Spravato (treatment-resistant depression), Invega (long-acting antipsychotic)
  - **Cardiovascular / Pulmonary Hypertension** — Opsumit, Uptravi, Xarelto (royalty)
  - **Infectious Diseases** — Edurant, Symtuza
  - **Pulmonary Hypertension** — Opsumit
- **MedTech** ($33.8B FY25, +6%) — medical devices across:
  - **Surgery** (wound closure, biosurgery, surgical vision)
  - **Cardiovascular** (Abiomed Impella, Shockwave intravascular lithotripsy, Biosense Webster electrophysiology)
  - **Orthopaedics** (DePuy Synthes — being spun off / "shrinking to grow faster")
  - **Vision** (contact lenses, IOLs)

Revenue mix is recurring (pharma rx + medtech device + capital equipment), geographically diversified (~50% US, ~50% international).

#### Products & Services
- **Top pharma assets:** Darzalex, Carvykti, Tremfya, Erleada, Stelara (eroding), Rybrevant + Lazcluze (NSCLC bispecific combo), Spravato, Imbruvica.
- **Pipeline:** TAR-200 (intravesical bladder cancer), milvexian (Factor XIa anticoagulant — partnered with BMS), nipocalimab (FcRn for autoimmune), TAR-210, JNJ-2113 (oral IL-23), Tremfya new indications.
- **Top medtech franchises:** Abiomed (heart pump leadership), Shockwave (IVL), Biosense Webster (electrophysiology), Ethicon (surgical staplers/sutures), Acuvue contact lenses.
- **Recent / planned divestitures:** Kenvue separation complete (2023); orthopaedics ("DePuy") spin-off announced as part of MedTech reshaping.

#### Customer Base & Go-to-Market
- **Innovative Medicine:** hospitals, oncology centers, specialty pharmacies, payers; selling through ~30,000+ sales reps globally.
- **MedTech:** hospitals, ambulatory surgery centers, physicians; mix of capital equipment + consumables.
- **Geographic mix:** ~50% US, ~25% Europe, ~25% rest of world.
- No material customer concentration; major risk is **payer reimbursement** (Medicare Part D negotiation, IRA penalties, ESG drug-pricing pressure).

#### Competitive Position
J&J is one of the world's largest healthcare companies by revenue and market cap, with the most diversified pharma + medtech franchise of any peer:
- **Oncology** — Darzalex is the dominant myeloma franchise; Carvykti reaching blockbuster status post-manufacturing expansion.
- **Immunology** — managing the largest patent-cliff transition in industry history (Stelara → Tremfya + next-gen oral pipeline).
- **MedTech** — Top 3 in cardiovascular devices (with Medtronic, Abbott); top 3 in surgery (with Medtronic, Stryker).

Structural advantages: (1) **AAA credit rating** (one of only two non-financial AAAs in US); (2) **$100B+ FCF over rolling 5 years** to fund R&D + M&A + dividend; (3) **63 consecutive years of dividend increases** — Dividend Aristocrat; (4) **portfolio diversification** — pharma + medtech offset each other's patent cliffs and reimbursement cycles.

**Active risks:** (1) Stelara biosimilar erosion in immunology (Q4 2025 Stelara sales -49%); (2) **talc litigation** — 67,000+ ovarian cancer lawsuits unresolved after 3 failed bankruptcy attempts; (3) MedTech China weakness from VBP (volume-based procurement); (4) tariff exposure on imported medical devices.

#### Key Facts
- Founded: 1886
- Headquarters: New Brunswick, New Jersey
- Employees: ~138,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals + MedTech
- Market Cap: ~$420B
- Credit Rating: AAA (S&P, one of only 2 non-financial AAAs in US)
- Dividend Aristocrat: 63 consecutive years of increases
- 2025 Revenue: $94.2B
- 2026 Guide: ~$100.5B (+~6%)

## Financial Snapshot

---
ticker: JNJ
step: 04
generated: 2026-05-11
source: quick-research
---

### Johnson & Johnson (JNJ) — Financial Snapshot

(FY2023 figures reflect "Old J&J" with Kenvue consumer health; FY2024+ are continuing-operations basis after May 2023 Kenvue separation.)

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY (FY25) |
|--------|--------|--------|--------|------------|
| Sales (continuing ops basis) | $85.2B | $88.8B | $94.2B | +6.0% |
| Innovative Medicine Revenue | $54.8B | $57.0B | $60.4B | +6.0% |
| MedTech Revenue | $30.4B | $31.9B | $33.8B | +6.1% |
| Adjusted Operational Growth | n/a | n/a | +4.2% | (constant currency, ex-divestitures) |
| GAAP EPS | $7.81 | $5.79 | $11.03 | +90% (vs. one-time charges in FY24) |
| Adjusted EPS | $10.07 | $9.98 | $10.79 | +8.1% |

#### Segment Detail — Q1 2026 (most recent quarter)

| Asset / Segment | Q1 2026 | YoY |
|-----------------|---------|-----|
| Darzalex (oncology) | $3.96B | +23% |
| Tremfya (immunology) | $1.61B | +68% |
| Carvykti (CAR-T) | $597M | +62% |
| Stelara (legacy) | -49% (Q4 2025 commentary) | LOE |
| MedTech segment | $8.6B | +8% |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$25B |
| Capital Expenditures | ~$4.5B |
| Free Cash Flow | $20.4B |
| Dividends Paid | $12.4B (61% payout ratio of FCF) |
| Share Repurchases | ~$1B–3B (variable) |
| Cash & Marketable Securities | ~$22B |
| Total Debt | ~$45B |
| Net Cash Position | ~-$23B (manageable; AAA-rated) |
| Q4 2025 Dividend Hike (Apr 2026) | $1.30 → $1.34 (+3%, 64th consecutive year) |
| FY26 FCF Target | ~$21B |

#### Key Ratios (approximate)
- P/E: ~17x (FY25 adjusted) | EV/EBITDA: ~13x | FCF Yield: ~4.9%
- Revenue Growth (FY25): +6.0% | FCF Margin: ~22%
- Dividend Yield: ~3.0% | Payout Ratio: ~62% of FCF
- Credit Rating: AAA (one of only 2 non-financial AAAs in US)
- Operating Margin: ~26% (consolidated adjusted)

#### Growth Profile
2026 marks a key inflection: J&J management explicitly framed the Stelara patent cliff as **"in the rearview mirror"**, freeing growth momentum from oncology + immunology + medtech. Initial 2026 guide of $100.5B in revenue was raised to $100.8B (+7%) on Q1 strength. Key growth drivers in 2026:
- **Oncology** (Darzalex +23%, Carvykti +62%, Rybrevant/Lazcluze NSCLC ramp)
- **Immunology** (Tremfya +68% as Stelara replacement; new Icotrokinra oral psoriasis approval)
- **MedTech** (Abiomed Impella, Shockwave IVL, electrophysiology +mid-teens)

Long-term ambition is **$100B+ sales** by 2026 (largely achieved) and pathway to ~$120B by 2030 driven by oncology + immunology pipeline (TAR-200, milvexian, nipocalimab, TAR-210).

#### Forward Estimates
2026 Guide (raised in Q1):
- Reported Sales: $100.8B (+7.0% midpoint)
- Adjusted EPS: $11.55 (+7.1% midpoint)
- FCF target: ~$21B

Bull case: Oncology pipeline drives $25B+ → $35B+ over 5 years; MedTech recovery in China; Carvykti supply catches demand → blockbuster scale; talc litigation finally resolved. Bear case: Stelara erosion accelerates further; talc verdicts exceed reserves (one $1.5B verdict in Dec 2025); MedTech China VBP pressure persists; tariff headwinds on imported devices.

## Recent Catalysts

---
ticker: JNJ
step: 12
generated: 2026-05-11
source: quick-research
---

### Johnson & Johnson (JNJ) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Stelara patent cliff "in the rearview mirror"** — Management's explicit Q4 2025 framing. Stelara erosion is already in the base (-49% in Q4 2025); Tremfya growing +68% YoY is more than fully replacing the lost revenue. With the largest LOE absorbed, the company exits 2026 with a cleaner growth setup.
2. **Oncology franchise compounding at 20%+** — Darzalex $3.96B (+23%), Carvykti $597M (+62%) in Q1 2026; oncology going from $20B to $25B YoY. Pipeline additions (TAR-200 bladder, Rybrevant + Lazcluze NSCLC bispecific, AKEEGA prostate) add multi-billion potential.
3. **Immunology Tremfya + oral IL-23 (Icotrokinra) backstops Stelara LOE** — Tremfya at +68% in Q1; Icotrokinra (oral IL-23) approved March 2026 — first-in-class oral peptide for plaque psoriasis. Together they secure the immunology franchise long-term.
4. **MedTech +8% growth with cardiovascular leadership** — Abiomed Impella, Shockwave IVL, Biosense Webster electrophysiology growing high-single-digit / low-teens. Orthopaedics spin-off ("DePuy" separation) further focuses MedTech on highest-growth segments.
5. **AAA balance sheet + $21B FCF target for 2026** — One of only two non-financial AAA-rated US companies. $21B FCF funds ~$13B dividend + buybacks + ~$5–10B M&A optionality. 64 consecutive years of dividend increases — Dividend Aristocrat.
6. **Talc resolution optionality** — Multiple paths to resolution: continuation in tort system, settlement of remaining claims, or fourth bankruptcy attempt. Any clean resolution removes a multi-year overhang and could re-rate the multiple by 1–2 turns.
7. **Defensive positioning + dividend yield ~3%** — J&J is the highest-quality defensive name in healthcare, with ~$94B revenue, AAA credit, and minimal recession sensitivity.

#### Bear Case Risks

1. **Talc litigation — 67,000+ ovarian cancer cases unresolved** — Despite three failed bankruptcy attempts, J&J remains in the tort system. December 2025 $1.5B verdict signals continued multi-billion exposure. If California consolidated cases produce a multi-billion verdict, total exposure could exceed $20–30B vs. current ~$11B in reserves.
2. **Stelara biosimilar erosion still accelerating** — Q4 2025 -49%; multiple biosimilars from Amgen, Sandoz, others. Stelara base case is ~$3B in 2027 vs. ~$11B in 2023. If Tremfya conversion slows, immunology growth disappoints.
3. **MedTech China VBP pressure** — Volume-based procurement (VBP) in China continues to pressure pricing on orthopaedic, cardiovascular, and surgery devices. MedTech China remains a multi-quarter headwind.
4. **IRA Medicare drug-price negotiations** — Imbruvica, Stelara, Xarelto already subject to negotiated prices starting 2026; more J&J drugs eligible in 2027–28. Pricing pressure is structural.
5. **Tariff exposure on imported devices** — MedTech components and finished devices imported from various Asian/European facilities. 2026 trade tensions could compress gross margin.
6. **Pipeline single-product risk** — While diversified, certain late-stage assets (milvexian, nipocalimab, TAR-200) are individually meaningful — readout failures would dent the long-term growth narrative.
7. **DePuy spin-off execution risk** — Carve-out of orthopaedics adds operational complexity and short-term distraction.

#### Upcoming Events
- **Q2 2026 earnings (mid-July 2026)**: Mid-year FY26 guide check.
- **TAR-200 (bladder cancer)**: Phase 3 data readouts through 2026.
- **Milvexian (Factor XIa anticoagulant)**: Multiple Phase 3 readouts with BMS — major potential blockbuster in stroke prevention.
- **Nipocalimab (FcRn for autoimmune)**: Expanding indications through 2026–27.
- **DePuy (orthopaedics) spin-off**: Timeline TBD; execution milestones key.
- **Talc litigation milestones**: California MDL hearings, individual state trials.
- **IRA negotiated price disclosures**: Annual updates affecting Imbruvica, Stelara, Xarelto.

#### Analyst Sentiment
Consensus rating is **Buy / Overweight** (~70% Buy, 28% Hold, 2% Sell). Price targets cluster $185–205 vs. trading ~$170–180 (~8–15% implied upside). Bull case targets ~$220 on oncology pipeline + talc resolution; bear case ~$150 on talc verdict materialization. Morgan Stanley, Wells Fargo, Goldman maintain Buy/Overweight; Berenberg Hold given valuation.

#### Research Date
Generated: 2026-05-11

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/jnj
- Full research API: GET /api/v1/research/JNJ/memo
- Coverage universe: /stocks